ID Week 2025 October 19-22 Atlanta, GA

Conference Reports for NATAP


ID Week 2025 October 19-22 Atlanta, GA

	PREFER-LA: People with HIV (PWH) in the United States with Prior Adherence Challenges with Oral Antiretroviral Therapy (ART) Prefer Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) Therapy After Switch - (11/04/25) Real-World Persistence to Long-Acting Cabotegravir Versus Oral PrEP for HIV Prevention in Participants Using a Digital Health Companion Tool (AURORA Study) - (11/04/25) Rapid Point-of-Care Hepatitis C RNA Test-to-Treat in Persons Experiencing Homelessness through Street Based Initiatives in Detroit, Michigan - (11/04/25) Low Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients in a Mobile and Telehealth HCV Elimination Program - (11/04/25) Hepatitis C virus treatment during pregnancy using glecaprevir/pibrentasvir - (11/04/25) Safety, Tolerability, and Outcomes of SofosbuviR/Velpatasvir in Treatment of Chronic Hepatitis C Virus during Pregnancy: Interim results from the STORC study - (11/04/25) Hepatitis C treatment during pregnancy Implementation of a shared decision-making care model - (11/04/25) Integrated Obstetric and Addiction Care Promotes Antepartum STI Screening and Poses Opportunities for Preventing the Vertical Transmission of HIV, HCV, and Syphilis - (11/04/25) Hepatitis C Virus Care Continuum Among People Who Inject Drugs - (11/04/25) Influence of Nucleos(t)ide Analogue Use With Bulevirtide on Treatment Outcomes in Chronic Hepatitis Delta - (11/04/25) Updates on Long COVID Therapeutics - (11/04/25) Home CAB/RPV Provides Novel Approach to Achieve Viral Suppression in PWH With Adherence Challenges - (11/02/25) Acceptability, Feasibility and Appropriateness of the Mobile Outreach Retention and Engagement (MORE) Program and Home Long-Acting Cabotegravir/Rilpivirine (CAB+RPV LA) Injections for People with HIV (PWH) Experiencing Adherence Challenges at Whitman-Walker Health in Washington D.C - (11/02/25) Effect of Hospitalization on Cognitive Function in People with HIV - (11/02/25) The Association of Steatotic Liver Disease [fatty liver] and Cardiovascular Disease Risk in a Large Cohort of People with Human Immunodeficiency Virus - (10/31/25) Low Statin Use in Bronx, NY: OPTIMIZING STATIN USE FOR PRIMARY PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN PEOPLE LIVING WITH HIV - (10/31/25) Change in Utilization of Statin Therapy Among People with HIV with the Recent Guideline Changes at a Ryan White Clinic in New Orleans, Louisiana - (10/31/25) PERFORMANCE OF ANTHROPOMETRIC MEASURES FOR SCREENING EXCESS VISCERAL ADIPOSE TISSUE IN WOMEN WITH HIV - (10/31/25) Evaluation of Treatment Satisfaction and Experiences Among People With HIV When Switching to B/F/TAF From CAB + RPV: Results From the Phase 4 EMPOWER Study - (10/31/25) A New Model of HIV Disease Progression Based on the Accumulation of Non-AIDS Comorbidities - (10/31/25) Frailty PWH in India - (10/31/25) On-time Injection Adherence and Persistence Among People with HIV Engaged in Primary Care on Long-Acting Cabotegravir/Rilpivirine - (10/31/25) Evaluation of Treatment Satisfaction and Experiences Among People With HIV When Switching to B/F/TAF From CAB + RPV: Results From the Phase 4 EMPOWER Study - (10/31/25) A Phase 4 Study to Evaluate the Safety and Efficacy of Oral B/F/TAF After Discontinuing Injectable CAB + RPV - (10/31/25) Lenacapavir Adherence and Effectiveness Over 2 Years of Use in the OPERA Cohort - (10/30/25) Few differences in persistence and virologic outcomes across age groups among CAB+RPV LA users: Findings from the OPERA Cohort - (10/30/25) Real-World Insights of the Financial Metrics of a Long-Acting Injectable CAB/RPV Program - (10/30/25) Zoster Vaccination in People Living with HIV Is Associated with Reduced Mortality and Cardiovascular Risk: A Real-World Matched Cohort Study Zoster Infection & Vaccination as Determinants of Vascular and Cognitive Outcomes in PLWH - (10/30/25) Virologic Outcomes with Lenacapavir in Heavily Treatment-Experienced People with HIV: A Multi-Center Real-World Study - (10/30/25) Human Immunodeficiency Virus (HIV) Testing and Evidence of HIV Among Real-World Long-Acting Pre-Exposure Prophylaxis (PrEP) Users in a United States Claims Database: Results From the PrEPFACTS Study - (10/30/25) Frailty in Older People with HIV - (10/30/25) Changes in Neurocognition and Mood in People Aging with HIV - (10/30/25) Clinical Outcomes of Long-Acting CAB+RPV in People with HIV Aged 60 and Older - (10/30/25) Safety and Effectiveness of Long-Acting Cabotegravir/Rilpivirine in People with HIV and Severe Renal Impairment (CAPRI) - (10/30/25) The US REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV - (10/30/25) The Global REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living With HIV - (10/30/25) Characterizing Substance Use in Older Adults Living with HIV - (10/29/25) High Prevalence of Chemsex in PrEP Users in Buenos Aires, Argentina - (10/29/25) Polypharmacy, Drug-Drug Interactions, and Risk of Hospitalization [deaths, comorbidities, blacks, linked] among Veterans with HIV Taking 2-, 3-, and 4-Drug Antiretroviral Therapy Regimens - (10/29/25) TESAMORELIN (EGRIFTA WR AND EGRIFTA® ) FORMULATIONS: BIOEQUIVALENCE IN HEALTHY PARTICIPANTS - (10/29/25) Healthcare Utilization and Costs in People Living with HIV and Cardiovascular Disease in the United States - (10/29/25) Healthcare Utilization and Costs in People Living with HIV and Neuropsychiatric Disorders in the United States; associated with higher comorbidities rates - (10/29/25) Effectiveness of Doxycycline Post-Exposure Prophylaxis for STI Prevention in HIV-Positive Individuals: A Two-Year Retrospective Study From the Brooklyn HEAT Clinic - (10/29/25) Association of HIV Pre-exposure Prophylaxis Initiation and Persistence with Prior Visit with the PrEP Prescriber Among Cisgender Women in the Bronx, NY, 2012-2023 - (10/29/25) Global survey reveals the ongoing impact of long COVID-19 on medically vulnerable populations, five years on - (10/29/25) Oral Weekly Islatravir + Lenacapavir, Efficacy, PK- Update - (10/27/25) IN-PATIENT MORTALITY TRENDS CAUSED BY HIV INFECTION IN THE UNITED STATES: A RETROSPECTIVE NATIONAL DATABASE HEALTHCARE RESOURCE UTILIZATION ANALYSIS FROM 2016-2022 - (10/29/25) Hospitalization Patterns and ART Use Among Insured Adults with HIV in the United States, 2016-2021 - (10/29/25) No Clinically Significant Drug-Drug Interactions With Coadministration of Feminizing or Masculinizing Hormone Therapy and Twice-Yearly Lenacapavir PrEP in Gender-Diverse Persons - (10/29/25) PrEP Utilization Patterns and Indications in a Cohort of HIV-Negative Individuals - (10/29/25) Real-World Sexually Transmitted Infection Testing Patterns Among Individuals Using Pre-Exposure Prophylaxis for HIV-1 Prevention in the United States - (10/29/25) Phase 2 Pharmacokinetics and Anti-Drug Antibody Results of the Investigational Twice-Yearly HIV-1 Treatment Regimen Lenacapavir, Teropavimab, and Zinlirvimab - (10/28/25) Pooled Safety and Tolerability of Twice-yearly Lenacapavir with Teropavimab and Zinlirvimab For HIV-1 Treatment - (10/28/25) Evaluation of Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet of Islatravir and Lenacapavir - (10/28/25) Prevalence of Integrase HIV-1 Drug Resistance Mutations in the United States: 2019-2024 - (10/28/25) Efficacy and Safety by Age After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results From Two Phase 3 Randomized, Active-Controlled Studies in Adults Living With HIV-1 - (10/23/25) Favorable Adherence and Safety of Twice-Yearly Subcutaneous Lenacapavir for PrEP Among PURPOSE 2 Participants Who Used Substances - (10/23/25) PREFER-LA: People with HIV (PWH) in the United States with Prior Adherence Challenges with Oral Antiretroviral Therapy (ART) Prefer Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) Therapy After Switch - (10/23/25) Improved Adherence and Viral Control in Real-World Study of People with HIV (PWH) in the United States with Adherence Challenges on Oral Antiretroviral Therapy (ART) Switching to Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA). - (10/23/25) Efficacy and Safety by Sex Assigned at Birth After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results From Two Phase 3 Randomized, Active-Controlled Studies in Adults Living With HIV-1 - (10/23/25) Safety and Efficacy of Doravirine/Islatravir (DOR/ISL) 100/0.25 mg Once Daily (QD) After ISL Dose Reduction From 0.75 mg: Week 48 Results From an Open-Label Phase 3 Study - (10/23/25) Switching to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily Maintains Viral Suppression Through Week 48 in the Presence of Archived NNRTI Resistance-Associated Mutations and/or M184I/V in Proviral DNA - (10/23/25) Modeling Confirms Islatravir 0.25 mg Administered Daily Has No Adverse Effect on Total Lymphocyte or CD4+ T-Cell Counts in People Living With HIV - (10/23/25) Modeling Confirms Islatravir 0.25 Administered Daily Has No Adverse Effect on Total Lymphocyte or CD4+ T-Cell Counts in PLWH - (10/23/25) Population Pharmacokinetic Analysis of Islatravir and the Impact of Intrinsic Factors in Participants With HIV-1 - (10/23/25) ViiV Healthcare showcases breadth of clInIcal and real-world evIdence at EACS and IDWeek 2025 - (10/09/25)